Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Carcinoma 1

Interventions

pembrolizumab 6Paclitaxel 3Docetaxel 3Cyclophosphamide 3eribulin 2Oncolytic Virotherapy 2tislelizumab 1tirbanibulin 1spartalizumab 1poly ICLC 1pertuzumab 1pemigatinib 1pegfilgrastim 1obinutuzumab 1ixabepilone 1fludarabine phosphate 1fludarabine 1etirinotecan pegol 1efineptakin alfa 1durvalumab 1atezolizumab 1aldesleukin 1advexin 1Yoga 1Vinorelbine 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Ritonavir 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Meperidine × Breast × Clear all
NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
36 enrolled 7 charts
Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡